Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Health Catalyst Inc (NASDAQ: HCAT) was $7.53 for the day, down -1.57% from the previous closing price of $7.65. In other words, the price has decreased by -$1.57 from its previous closing price. On the day, 0.52 million shares were traded. HCAT stock price reached its highest trading level at $7.795 during the session, while it also had its lowest trading level at $7.32.
Ratios:
Our analysis of HCAT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.41 and its Current Ratio is at 1.41. In the meantime, Its Debt-to-Equity ratio is 1.03 whereas as Long-Term Debt/Eq ratio is at 0.37.
On January 03, 2024, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $11.
On January 03, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $14.Barclays initiated its Overweight rating on January 03, 2024, with a $14 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 15 ’24 when Llewelyn Linda sold 1,365 shares for $8.50 per share. The transaction valued at 11,602 led to the insider holds 112,910 shares of the business.
LINDA LLEWELYN bought 1,365 shares of HCAT for $11,534 on Nov 15 ’24. On Nov 05 ’24, another insider, LeSueur Daniel, who serves as the Chief Operating Officer of the company, sold 5,209 shares for $7.70 each. As a result, the insider received 40,127 and left with 129,690 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 458183200 and an Enterprise Value of 435258880. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.37 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at 1.441 whereas that against EBITDA is -13.567.
Stock Price History:
Over the past 52 weeks, HCAT has reached a high of $11.41, while it has fallen to a 52-week low of $5.42. The 50-Day Moving Average of the stock is -7.75%, while the 200-Day Moving Average is calculated to be 1.97%.
Shares Statistics:
HCAT traded an average of 477.39K shares per day over the past three months and 576400 shares per day over the past ten days. A total of 58.30M shares are outstanding, with a floating share count of 58.26M. Insiders hold about 4.25% of the company’s shares, while institutions hold 87.33% stake in the company. Shares short for HCAT as of 1730332800 were 2844258 with a Short Ratio of 5.96, compared to 1727654400 on 2651596. Therefore, it implies a Short% of Shares Outstanding of 2844258 and a Short% of Float of 4.77.
